GLP-1 Medications Compared: Ozempic vs. Wegovy vs. Mounjaro vs. Trulicity

Last Updated: March 26, 2026

Six GLP-1 receptor agonist medications are at the center of the mass tort litigation consolidated in MDL 3094. While all six drugs share a similar mechanism of action — mimicking the incretin hormone GLP-1 to regulate blood sugar and appetite — they differ in active ingredient, manufacturer, approved uses, and administration method. All six are included in the current litigation.

Ozempic (Semaglutide) — Novo Nordisk

Ozempic is the most widely recognized drug in the GLP-1 litigation. Approved by the FDA in 2017 for type 2 diabetes, it contains semaglutide and is administered as a weekly subcutaneous injection. Ozempic became a cultural phenomenon due to widespread off-label use for weight loss, which dramatically expanded its user base beyond the diabetic population. The injuries most commonly alleged in Ozempic claims include gastroparesis, bowel obstruction, gallbladder disease, and pancreatitis. A 2023 JAMA study found elevated rates of gastrointestinal adverse events among semaglutide users compared to other diabetes and weight-loss medications.

Wegovy (Semaglutide) — Novo Nordisk

Wegovy contains the same active ingredient as Ozempic — semaglutide — but at a higher dose (2.4 mg vs. up to 2.0 mg). It was approved by the FDA in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Because Wegovy users are often otherwise healthy individuals seeking weight loss rather than managing diabetes, plaintiffs argue that the manufacturer had a heightened duty to warn about serious gastrointestinal risks. Wegovy’s injury profile mirrors Ozempic’s, including gastroparesis, gallbladder disease, and NAION (vision loss).

Mounjaro (Tirzepatide) — Eli Lilly

Mounjaro stands apart as a dual GIP/GLP-1 receptor agonist, activating two incretin receptors rather than one. Manufactured by Eli Lilly and approved in 2022, it contains tirzepatide and has shown particularly strong results for both blood sugar control and weight loss in clinical trials. A version branded as Zepbound was approved in 2023 for weight management. The dual mechanism produces a potent effect on gastric emptying, which drives the same gastroparesis risk seen with other GLP-1 drugs. Mounjaro cases name Eli Lilly as the defendant and are consolidated in MDL 3094 alongside semaglutide-based claims.

Trulicity (Dulaglutide) — Eli Lilly

Trulicity is one of the older GLP-1 drugs on the market, approved by the FDA in 2014 for type 2 diabetes. It contains dulaglutide and has been prescribed to millions of patients over more than a decade. Trulicity’s longer market history means more years of adverse event data in the FDA FAERS database, documenting gastrointestinal injuries including gastroparesis, bowel obstruction, and pancreatitis. Because Trulicity has been available longer, some claimants may face statute of limitations considerations — though the discovery rule may protect those who were unaware of the drug’s role in their injuries.

Saxenda (Liraglutide) — Novo Nordisk

Saxenda contains liraglutide and was approved in 2014 for chronic weight management. Unlike the weekly injections of Ozempic, Wegovy, and Mounjaro, Saxenda requires daily injections. It is also sold under the brand name Victoza for type 2 diabetes. The FDA has long required gallbladder-related warnings on Saxenda’s label, and its prescribing information includes warnings about acute pancreatitis. Saxenda litigation involves additional allegations about whether the manufacturer provided sufficient warnings about the severity of gastrointestinal risks, given that some side effects were already acknowledged on the label.

Rybelsus (Oral Semaglutide) — Novo Nordisk

Rybelsus is the only oral GLP-1 medication currently on the market. Approved in 2019 for type 2 diabetes, it contains semaglutide in a daily tablet form rather than an injection. Despite the different delivery method, the active ingredient is identical to Ozempic and Wegovy, and the oral formulation does not eliminate the gastrointestinal risks associated with semaglutide’s mechanism of action. Rybelsus claims are consolidated with other semaglutide cases in the MDL, and Novo Nordisk faces allegations regarding all three of its semaglutide products.

Key Differences That Matter for Your Case

When evaluating a potential GLP-1 claim, several factors vary by medication:

• Manufacturer: Novo Nordisk manufactures Ozempic, Wegovy, Saxenda, and Rybelsus. Eli Lilly manufactures Mounjaro and Trulicity. Your claim is against the manufacturer of the specific drug you took.
• Approval date: Drugs approved earlier (Trulicity 2014, Saxenda 2014) have longer adverse event histories. Newer drugs (Mounjaro 2022) have rapidly growing case counts.
• Dose and frequency: Higher doses and longer durations of use may strengthen the causal connection between the drug and your injury.
• Approved indication: Whether you took the drug for diabetes or weight loss can affect the failure-to-warn analysis.

Regardless of which GLP-1 drug you took, if you developed a qualifying injury — gastroparesis, bowel obstruction, gallbladder disease, pancreatitis, or NAION — you may have a viable legal claim. See our eligibility guide for a full breakdown.

Frequently Asked Questions

Does it matter which GLP-1 drug I took for my lawsuit?

All six GLP-1 medications listed above are included in MDL 3094. Your specific drug determines which manufacturer is the defendant, but the legal framework and pretrial process are the same for all GLP-1 claims.

Is Mounjaro more dangerous than Ozempic?

Clinical data does not clearly establish that one GLP-1 drug carries a dramatically higher risk of gastrointestinal injuries than another. All GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action. Mounjaro’s dual-receptor mechanism is distinct, but the injury profile is similar across the class.

I switched between multiple GLP-1 drugs. Can I still file a claim?

Yes. Taking multiple GLP-1 drugs does not disqualify you. In some cases, prolonged exposure across multiple medications with the same mechanism of action may actually strengthen the causal connection to your injury.

Are there GLP-1 drugs not listed here that are part of the lawsuit?

The MDL broadly covers GLP-1 receptor agonist claims. If you took a GLP-1 medication not listed in this comparison and developed a serious injury, consult with an attorney to determine whether your case fits within the litigation. For a full overview of which drugs qualify, see our eligibility guide.

Take the Next Step

Understanding which GLP-1 medication you took — and how it fits into the broader litigation — is an important first step in evaluating your legal options. All six drugs listed above are actively part of MDL 3094.

If you or a loved one suffered serious injuries after taking any GLP-1 medication, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629